PI16 and hepatocellular carcinoma: In concentrations of both 5 μM sorafenib and 10 μM sorafenib, we observed that HCC cells in which PI16 was suppressed were more sensitive to sorafenib treatment in MHCC‐97H cells (Figure 2A and B); while PI16 overexpression in HepG2 cells could increase resistance (Figure 2C and D).